GIOTRIF^® (afatinib) in Squamous Cell Carcinoma

GIOTRIF^® (afatinib) as monotherapy is indicated for patients with NSCLC of squamous histology progressing on or after platinum-based chemotherapy¹

See the efficacy benefits of using GIOTRIF^® (afatinib) after chemotherapy in unselected 2nd-line SqCC.²Click here.

Rationale for targeting ErbB in 2nd-line SqCC

A comprehensive genomic analysis of 178 squamous cell carcinoma tumours by the Cancer Genome Atlas Research Network identified a potentially targetable gene or pathway alteration in 96% samples studied²
Identified potential oncogenic drivers included the ErbB family, FGF receptor family, JAKS and the PI3K pathway²
GIOTRIF^® (afatinib) is a highly selective irreversible ErbB family blocker.^3,4 Find out more.

Want to find out about GIOTRIF^® (afatinib) in 1st-line EGFR M+ non-small-cell lung cancer? Click here to find out more.

FGF=fibroblast growth factor receptor, JAKS, Janus Kinase, NSCLC=non-small-cell lung cancer, PI3K=phosphoinositide, SqCC=squamous cell carcinoma

References

1: GIOTRIF^® (afatinib), Summary of Product Characteristics, 2018.
2: The Cancer Genome Atlas Research Network. Nature 2012;489(7417):519–525.
3: Solca F, et al. J Pharmacol Exp Ther 2012;343(2):342–350.
4: Li D, et al. Oncogene 2008;27(34):4702–4711.

You may also be interested in...

Dosing

GIOTRIF^® (afatinib) dose modification can be an important strategy to help manage adverse reactions.

Learn more

AE management

Common AEs associated with GIOTRIF^® (afatinib) are generally well managed with supportive care.

Learn more

This site uses cookies to improve your browsing experience. By using this site, you agree to their use.

Cookie policy

Disclaimer

You're now leaving our website...

Using this link will let you leave a website of Boehringer Ingelheim International GmbH (“BI”) or to a different domain under the control of BI. In the event that the linked site is not under the control of BI but under the control of a third party or an affiliate in the Boehringer Ingelheim group of companies, BI shall not be responsible for the contents, processing of personal data of any linked site or any link contained in a linked site, or any changes or updates to such sites. This link is provided to you only as a convenience, and the inclusion of any link does not imply endorsement by BI of the site.

Do you want to continue?

Continue Cancel

I am a Healthcare Professional outside the US and UK

Click here for international product information intended for Healthcare Professionals about afatinib for non-small-cell lung cancer treatment.

I am not a Healthcare Professional and I am outside the US and the UK

Click here for general international information about afatinib for non-small-cell lung cancer treatment.

Country-specific product information

Click here for country-specific product information intended for Healthcare Professionals about afatinib for non-small-cell lung cancer treatment.

GIOTRIF® (afatinib) in Squamous Cell Carcinoma